MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why INBX Stock advanced +0.49% Today — RQD Quant Desk Flash
$73.65 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $73.58
Inhibrx Biosciences Inc. (INBX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.08B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $73.58 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY INBX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (42% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)
FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 31.2 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$95.01-5.5% Next Q
39
Q2 (-2Q)Grade E$89.83+4% Next Q
36
Q3 (-1Q)Grade E$93.38-21.1% Next Q
34
CurrentGrade E$73.65-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INBX Turnaround Squeeze
While INBX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($102.34) and Max Pain ($77.33) forces dealer call-delta covering toward $163.05.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INBX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INBX Stock advanced +0.49% Today — RQD Quant Desk Flash
Inhibrx Biosciences Inc. (INBX) advanced +0.49% to $73.65, trading at 17% of its 52-week range ($57.3 – $155.29). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 17% of its 52-week range ($57.3 – $155.29) with RSI-14 at 31.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $73.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live INBX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBX)
- ✓Walkthrough of INBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.00%📐 HORIZONTAL RANGE
2026-10-30O $72.04H $73.65L $66.80C $73.65VOL 438.8K
RES: $162.0SUP: $62.87SMA50: $102.3SMA200: $92.14
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INBX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INBX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBX)
Health Care Rank #911 of 1016
⚔️ IMTX vs INBX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INBX vs. IMTX, CGEM, ODTX, PRME)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Inhibrx Biosciences Inc. (INBX) ranks #911 by composite RQD confidence (31/100, grade E) and #355 by equity capitalization ($1.08B). Within this direct 5-issuer industry benchmark cohort, INBX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with INBX at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INBX
ACTIVE
Inhibrx Biosciences Inc. | E | 31/100 | — | — | -35.0% | +0.49% | $1.08B | Benchmark Subject |
| IMTX Immatics N.V. | D+ | 52/100 | — | — | — | -0.54% | $1.09B | /imtx-vs-inbx → |
| CGEM Cullinan Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -0.71% | $994.3M | /cgem-vs-inbx → |
| ODTX Odyssey Therapeutics Inc. | C- | 59/100 | — | — | — | +1.48% | $953.0M | /odtx-vs-inbx → |
| PRME Prime Medicine Inc. | E | 21/100 | — | — | -35.0% | -2.24% | $950.4M | /prme-vs-inbx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002007919In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported GAAP revenue of $1.3M (+550.0% vs. FY2024 revenue of $200.0K , and -27.8% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$129.8M, and free cash flow of -$129.8M (+34.1% YoY). On the balance sheet, INBX closed FY2025 with $146.5M in total assets against $100.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.3M | -$140.1M | -$129.8M | -$129.8M | $146.5M | $100.6M |
| FY2024 (FY) | 2024-12-31 | $200.0K | $1.69B | -$194.4M | -$197.0M | $180.8M | $0 |
| FY2023 (FY) | 2023-12-31 | $1.8M | -$241.4M | -$193.3M | -$193.3M | — | — |
3. INBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $73.65 (+0.49% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBX ranks #911 in composite RQD confidence.
How does INBX compare to IMTX and CGEM in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.09B) and CGEM (Cullinan Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INBX?
Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INBX trading relative to its 50-day, 200-day, and 52-week technical levels?
INBX last traded at $73.65 (+0.49% on volume of 358,799 shares), positioning the stock -28.03% below its 50-day simple moving average ($102.34) and -20.07% below its 200-day simple moving average ($92.14). Across its 52-week range of $57.30 to $155.29, INBX sits at the 16.7% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($64.44 to $82.86).
INBX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INBX stock moving today?
Why INBX Stock advanced +0.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.